GBIO Generation Bio
- 3.690
- -0.100-2.64%
Generation Bio News
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
Wedbush: Reiterates the Generation Bio (GBIO.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush: Reiterates the Generation Bio (GBIO.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush Remains a Buy on Generation Bio (GBIO)
Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Generation Bio (GBIO)
Generation Bio Q1 2024 Adj EPS $(1.12) Misses $(0.41) Estimate, Sales $4.059M Beat $1.920M Estimate
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.41) by 173.17 percent. The company reported quarterly sales of $4.059 mi
Generation Bio | 10-Q: Quarterly report
Generation Bio 1Q Loss/Shr $1.12 >GBIO
Generation Bio 1Q Loss/Shr $1.12 >GBIO
Press Release: Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Generation Bio Announces the Presentation of Preclinical Data on IqDNA and CtLNP Platforms at the ASGCT 27th Annual Meeting
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six
Generation Bio Price Target Maintained With a $10.00/Share by Needham
Generation Bio Price Target Maintained With a $10.00/Share by Needham
Needham: Reiterates Generation Bio (GBIO.US) rating and adjusted from buy to buy rating, target price is $10.00.
Needham: Reiterates Generation Bio (GBIO.US) rating and adjusted from buy to buy rating, target price is $10.00.
Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)
Needham Reiterates Buy on Generation Bio, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $10 price target.
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Generation Bio GAAP EPS of -$0.53
Wedbush Reiterates Outperform on Generation Bio, Maintains $5 Price Target
Wedbush analyst David Nierengarten reiterates Generation Bio (NASDAQ:GBIO) with a Outperform and maintains $5 price target.
Analysis
Price Target
No Data
